Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
RTW Biotech Opportunities Ltd - Guernsey, Channel Islands-based investor in high-growth life science sectors - Notes Biogen Inc’s agreement announced last Thursday to acquire portfolio company Alcyone Therapeutics Inc for $85 million upfront plus milestone payments. Says the deal represents a 242% uplift on RTW’s $2.1 million carrying value of Alcyone, adding $5.0 million, or around 0.7%, to its August 31 NAV, where Alcyone represented approximately a 0.3% position. Alcyone is developing ThecaFlex DRx, an implantable device for intrathecal delivery of neurological therapies, which Biogen plans to deploy with its marketed drug Spinraza, with a launch targeted in 2028. The transaction its RTW’s second portfolio takeout this year, following Merck & Co Inc’s purchase of Verona Pharma PLC, and says it highlights embedded value in its private holdings.
Current stock price: $1.49, up 0.3% on Tuesday morning in London
12-month change: down 2.3%
Copyright 2025 Alliance News Ltd. All Rights Reserved.